Merck & Co., Inc. (MRK)
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key drugs Gardasil and Winrevair. Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement.
Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?
Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
This Biotech Stock Could Rocket 800%, Analyst Says
EF Hutton analyst Jason Kolbert initiated coverage of shares of cancer-immunotherapy biotech ImmunityBio with a Buy rating and a $30 price target on Wednesday.
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.
Merck (MRK) Advances While Market Declines: Some Information for Investors
Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close.
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.
Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Merck RSV jab has the potential to protect infants
Merck & Co Inc's (NYSE:MRK, ETR:6MK) experimental treatment for respiratory syncytial virus (RSV) has shown positive results in a mid- to late-stage trial, moving the company closer to seeking regulatory approval. The treatment, clesrovimab, aims to protect infants from RSV, a leading cause of hospitalizations in newborns and responsible for hundreds of infant deaths annually.
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants.
